Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental ...
SGT-003 is Solid Biosciences' lead gene therapy candidate designed to address the underlying cause of Duchenne muscular dystrophy. It utilizes a novel viral vector to deliver a functional dystrophin protein to muscle tissues, aiming to improve muscle function and slow disease progression.
Pain Points: Lack of functional dystrophin protein leading to progressive muscle degeneration and weakness in DMD patients.
Solutions: Restoration of dystrophin production through gene delivery, potentially stabilizing muscle health.
Target Users: Patients diagnosed with Duchenne muscular dystrophy.
Supply Chain
Viral vector manufacturing partnersGenetic material suppliersClinical research organizations (CROs)Specialized cold-chain logistics providers
SGT-212 is an experimental gene therapy developed to treat Friedreich’s ataxia, a rare genetic neuromuscular disease, by addressing the underlying genetic deficiency.
Pain Points: Genetic defects causing Friedreich’s ataxia and associated neurological and cardiac impairment.
Solutions: Genetic correction to mitigate the impacts of Friedreich’s ataxia.
Target Users: Patients diagnosed with Friedreich’s ataxia.
Supply Chain
Genetic research laboratoriesBiotech manufacturing facilitiesClinical testing partners
SGT-501 targets specific genetic mutations (RYR2 and CASQ2) associated with CPVT, a heart condition that causes irregular heartbeats, using a gene transfer approach to restore normal cardiac function.
Solid Biosciences' proprietary Capsid Library is an enabling technology designed to optimize the delivery of gene therapies across different tissue types, potentially improving efficiency and reducing side effects for a wide range of genetic diseases.
Price Range: N/A (Internal R&D platform)
Pain Points: Inadequate delivery of gene therapies to targeted organs and potential immune responses to standard vectors.
Solutions: Enhanced, specialized vectors that increase the safety and efficacy of genetic medicines.
Target Users: Internal R&D pipelines and potential future industry licensing partners.
Supply Chain
Computational research teamsLaboratory facilitiesGenomic synthesis service providers
